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Abstract
Ethical requirements of informed consent stipulate that patients approached to participate in a clinical trial be
provided with written information that must cover key aspects of the trial. For consent to be deemed “informed”,
potential participants should be provided with a range of information about the trials (e.g., the trial aims, the
anticipated benefits and potential risks of the trial, and their right to withdraw consent at any time). However, it is
well documented that simple provision of this information does not ensure that participants make truly informed
decisions. Decision aids, tools that have been shown in a treatment and screening context to support better-quality
decisions, are emerging as a possible vehicle to support decision making about trial participation. However,
information on how they should best be developed and evaluated in a clinical trial context is lacking. Therefore,
this article, drawing on theoretical and empirical insights, outlines a framework for the development and evaluation
of decision aids for people considering taking part in a clinical trial.
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Background
The requirement for informed consent to be sought from
potential participants when they are deciding whether to
enter a clinical trial is enshrined in the Declaration of
Helsinki and several other international and national regu-
lations [1–3]. These regulatory requirements were es-
tablished as a mechanism to protect participants from any
undue harm from research [1]. The regulations stipulate
that, for consent to be deemed “informed”, potential par-
ticipants should be provided with a wide range of informa-
tion elements, including the trial aims, methods, sources
of funding, any possible conflicts of interest, institutional
affiliations of the researcher, the anticipated benefits and
potential risks of the trial, what happens at the end of the
trial, and their right to withdraw consent at any time
without reprisal [1–3]. During the informed consent
process, potential participants are usually provided with
a written patient information leaflet (PIL) summarising
this information [3]. However, simply providing this
information does not, of itself, ensure that consent is
informed. Evidence from several studies illustrates that
current approaches to informed consent for clinical
trials—in particular, simple provision of information in
the PIL—may be suboptimal [4–6]. For example, some
have developed information leaflets without asking
potential participants what information they consider
key for supporting a decision to take part in a trial.
Others have focused solely on the printed information
without considering the conversation in which it is to be
placed [5, 6]. Many of these deficits have been targeted for
improvement through the development of interventions
to improve information provision [4–7]. However, these
interventions have tended to be narrowly focused on the
content and structure of information provision and
evaluate effectiveness by measuring outcomes such as
understanding, knowledge and trial recruitment rather
than potential wider outcomes such as decisional conflict
or regret [4–7].
Evidence from the treatment and screening decision-
making literature has identified that, for making “good”
decisions, the provision of information alone is not
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sufficient [8]. “Good” decisions can be thought of as those
that improve the match between the chosen decision and
the features that matter most to the informed patient [8].
Providing ways for people to be able to compare options,
facilitating the ability to make trade-offs between options,
and allowing people to weigh up potential outcomes of
decisions and assess how different outcomes matter to
them have all been shown to promote “good” decisions
[8]. These items, and others, are often included in so-
called “decision aids”, formal tools which help people
to participate in treatment (or screening) decisions
that involve weighing up associated benefits and
harms in the face of clinical uncertainty [8, 9]. Decision
aids have been shown to positively influence various
aspects of decision making across a range of treatment
and screening decisions [8, 9].
Decision aids for people considering taking part in a
clinical trial are emerging in the literature but remain
sparse [10]. A handful of feasibility or full trials evaluating
decision aids to inform decisions about trial participation
are reported in the literature and others are in the plan-
ning stage [11–17]. Early randomised comparisons show
that, in this setting, decision aids have potential promise
with regard to improving key decision outcomes (know-
ledge, values clarification, and decision conflict) and not
negatively affecting recruitment or intention to participate
[14–16]. However, most examples of decision aids for trial
participation are currently set within an oncology context;
there is a paucity of examples in other disease areas and
across a range of intervention choices. The reason for this
current focus in oncology is unclear, although intuitively it
may reflect a natural extension of the rich history of the
use of decision aids for treatment decisions in this context.
However, it is likely that different clinical contexts will
generate specific (both clinically and when considering
interventions being compared) issues for the design of
decision aids and these will have to be accommodated for
in the development process. As the appetite for decision
aids for trial participation grows, it is important that these
be developed in a rigorous and evidence-based way. There
are several reports that outline the overall and stepwise
process for developing decision aids for treatment and
screening decisions [18, 19]. However, there is no counter-
part that describes a comprehensive approach to the
development of trial participation decision aids. To this
end, this article describes a potential framework for the
development and formulation of prototype decision aids
to aid decisions of whether to participate (or not) in a
clinical trial on the basis of theoretical and empirical
insights. It describes the need to select an underpinning
theoretical approach to inform the development
process and steps that we believe should be undertaken
to successfully develop and evaluate candidate decision
aids in this context.
Within the general framework, the following steps are
proposed:
 Selecting an underpinning theoretical approach
to the development process
 Developing the decision aid
 Assessing and testing feasibility
 Evaluating the decision aid
 Implementing the decision aid in practice.
We illustrate the process by using case studies of the
development and evaluation of decision aids for two
exemplar trials. The first is a drug trial comparing two
active drugs versus placebo for the treatment of ureteric
stones (SUSPEND ISRCTN: 69423238, date of regis-
tration: 18 November 2010) and the other is a trial com-
paring two surgical procedures for the treatment of
haemorrhoids (eTHoS ISRCTN: 80061723, date of re-
gistration: 8 March 2010). Further information on each
of the host trials can be found in Table 1.
Selecting an underpinning theoretical approach to the
development process
Guidance previously written to inform the development of
decision aids for treatment decisions endorses the
Table 1 Characteristics of host trials
Trial characteristics eTHoS SUSPEND
Clinical condition Haemorrhoids Ureteric stones
Trial design Simple parallel design Simple parallel design
Sample size, number 800 1200
Recruitment
rate, percentage
74 56
Arms 2 3
Intervention Surgery Drug
1. Traditional excisional
haemorrhoidectomy
1. Calcium channel
blocker
2. Stapled
haemorrhoidopexy
2. Alpha blocker
3. Placebo
Blinding Participants and
outcome assessors
(for patient-reported
outcomes)
Participants, caregivers
and outcome assessors
Number of sites 31 24
Primary outcome
(clinical or patient-
reported and timing)
Patient-reported
at 2 years post-
randomisation
Clinical at 4 weeks and
patient-reported at
12 weeks post-
randomisation
Host trial participant characteristics
Age in years, median
(interquartile range)
49 (20–40) 44 (34–52)
Sex (percentage
who are females)
48 19
Gillies and Campbell Trials          (2019) 20:401 Page 2 of 11
identification or development of a guiding theoretical
framework to support decision-aid development [18–20].
Several theories and conceptual frameworks have been
used to develop treatment and screening decision aids
[21]. We reviewed a range of possible candidate frame-
works and identified the Ottawa Decision Support Frame-
work (ODSF) as being a highly relevant theoretical
framework to use for development of trial participation
decision aids. The ODSF is a descriptive framework that is
based largely on the construct of decisional conflict
(shown to be salient in a trial participation context [22])
but also includes input from various theories in psych-
ology, social psychology, social support, and economics
[22]. The ODSF assumes that there are unmet decisional
needs (e.g., knowledge deficits, decisional conflict, unreal-
istic expectations, unclear values, and unmet support)
that, once addressed, will result in improvements in
decision quality. This maps very well onto the known issues
within trial participation decisions as they are known to be
preference-sensitive decisions—decisions largely influenced
by a patient’s preferences and values [23].
We also recognised that decision aids involve multiple
components, interacting systems and processes; as such,
they also naturally fit the definition of a “complex inter-
vention” [11, 24]. Therefore, when considering how to
develop our trial participation decision aid, we also
deemed it important to appeal to the international
Medical Research Council (MRC) guidance on developing
and evaluating complex interventions [25]. The MRC
guidance suggests an iterative model of development and
testing of complex interventions through defined stages:
development, feasibility, evaluation and implementation.
An integration of both the MRC guidance and the
OSDF principles thus formed the underpinning theo-
retical approach to our development work.
Developing the decision aid
a. Identifying the need for trial participation decision aids
The guidance on the development of treatment and
screening decision aids recommends that the first step
focus on determining a need for the requirement of a deci-
sion aid (i.e., defining the scope and addressing decisional
needs) [18–20]. Our justification for the development of a
decision aid is based on two elements: (a) in the context of
trial participation, regulatory requirements stipulate that
the provision of information is a mandatory pre-requisite
to informed consent, and (b) there is no evidence on the
optimal method to support people’s decision making about
trial participation (see above). The guidance on developing
complex interventions and decision aid development
guidance complement the requirement to identify the
“need” for the decision aid by recommending that any
complex intervention being developed incorporate what is
already known on the interventions of interest [19, 25].
We also searched for evidence to ensure that an appro-
priate decision aid did not already exist. In our search for
evidence, we identified (a) reviews of decision aids for
treatment and screening and (b) reviews of interventions
(not solely decision aids) to improve informed consent to
trials [4, 7, 8]. However, we were not able to identify any
existing systematic review of decision aids specifically for
people considering trial participation. Therefore, we
conducted a wider search to review all of the available
evidence in this area [10]. The results of this wider review
also supported the conclusion that there remained a gap
in the evidence base for the development of a decision aid
in this field (only one eligible study was identified but it
did show evidence of benefit) in this context, but the
review also informed the shape and scope of the decision
aid (see below).
In addition to conducting a review of the published
evidence, we also contacted relevant experts to identify
any potentially relevant new, ongoing or unreported re-
search in this area. Specifically, we conducted a formal
survey of the Directors of the UK Clinical Research
Collaborations (UKCRC) registered Clinical Trial Units
[26]. We also canvassed the shared decision-making
community through the use of social media platforms.
The survey (which did not identify any ongoing studies in
the field at the time) and the systematic review (which
identified one study suggestive of benefit) provided evi-
dence to support the need for further research in this area.
Thus, on the basis of both the theoretical and empirical
evidence, we concluded there was a continuing need for
the development of a decision aid for trial participation.
b. Defining the scope
The literature review conducted above showed that
considerations for the development of a decision aid
would likely differ depending on factors such as the
phase of trial, whether prospective or retrospective con-
sent (e.g., for emergency trials) was being sought, and
whether proxy decision makers were those who would
provide the consent. As such, it was deemed crucial to
explicitly outline the scope of the decision aid at the out-
set of the development phase. In our context, the scope
and context for our prototype decision aids were phase
III effectiveness trials of interventions in adults with the
capacity to give their autonomous prospective consent
to participate (or not) in a clinical trial.
c. Identifying the content requirements
To determine what the content requirements of any trial
participation decision aid would be, we first conducted a
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concept-mapping exercise (a process that depicts relation-
ships between individual concepts). This concept-mapping
process brought together the evidence we identified from
the literature relating to factors that influence an indivi-
dual’s decision about whether (or not) to participate in a
clinical trial, the regulatory guidance on what information
participants have to and should be told when considering
trial participation, and the International Patient Decision
Aid Standards (IPDAS) content items [27]. This informa-
tion was broken down into individual items and “mapped”
to identify areas of convergence and divergence across the
three sources (Fig. 1). Items were assessed for duplication
of concepts and were reduced accordingly to generate a list,
supplemented with the divergent items, to produce a final
candidate item set.
This item set formed the basis of a Delphi survey to
assess consensus across stakeholders as to the core set of
items that should be included in a final decision aid. The
Delphi survey asked stakeholders (trialists, research nurses,
ethics committee chairs, decision support experts and
patients—both trial-naïve and trial-experienced) to rate the
importance of each item for inclusion in a trial partici-
pation decision aid—in essence to identify the core infor-
mation required to support decision making in participant
information for clinical trials. The full results of this Delphi
survey have been published previously [27]. In summary,
the Delphi survey results showed that many of the items
deemed important for decision making in treatment and
screening (e.g., information to help patients determine
what matters most to them, ensuring that the information
is balanced, and guidance on how to make a decision) are
also considered important in this context [27].
In addition to conducting the Delphi survey, we con-
ducted a review of existing PILs for clinical trials by using
a tool based on the IPDAS. The purpose of conducting
this review was to determine whether and how existing
PILs fulfil the requirements of decision aids. Again, the
results of this work have been published elsewhere [28]. In
brief, this work identified key areas where existing PILs
were lacking; as such, these areas (such as presenting
probabilities and clarifying and expressing values) should
be included in future trial participation decision aids [28].
The items agreed to by at least one stakeholder group in
the Delphi survey as being important (after two rounds of
rating) and those key informational gaps identified from the
review of PILs (total of 60 items across both pieces) were
carried through to the prototype development stage, de-
scribed in more detail below. Table 2 provides examples of
the types of informational items identified during this stage.
d. Creating the prototype decision aid
To create the actual prototype decision aid, we worked
through the key elements of the ODSF (introducing the
decision, describing potential benefits and risks and
probabilities in varying formats, clarifying and commu-
nicating values, and assessing unresolved needs and next
steps). We used the informational items generated from
the Delphi survey and the PIL review to populate the
appropriate sections. Presentation of information was
developed through working with graphic designers. Sample
pages from the decision aids for each of the two exemplar
trials are presented in Fig. 2.
Assessing and testing feasibility of the prototype decision
aids
The ODSF recommends that during the decision aid de-
velopment and piloting process there be stakeholder
engagement and that preferences for intervention delivery
be incorporated [22]. To undertake feasibility and piloting
of the new prototype decision aids, we undertook an
exploratory pilot of the prototype decision aids (so-called
“alpha testing” [19]). During the exploratory pilot, we also
sought stakeholders’ opinions about what the main object-
ive of the decision aid should be. Once the main objective
is explicit, appropriate outcomes to measure whether that
objective had been met (and thus whether the decision aid
had been effective) can be identified. Many of the re-
sponders suggested that support for informed decision
making (or similar e.g. informed choice) be the most
important outcome to determine the effectiveness of a de-
cision aid. However, others considered trial relevant out-
comes such as recruitment and retention rates to be the
main focus for evaluation (unpublished data).
It has also been noted that it is important for deve-
lopers to consider how the choice of delivery mode will
lend itself to review by ethics committees (i.e., if a web-
based platform is used, printouts of the content may
need to be provided for review) [29]. To date, most PILs
have been paper-based and hence we elected to deliver
the decision aids we developed as printed A5 booklets.
Not surprisingly, the stakeholders in our pilot had vary-
ing preferences (both within and between groups) relat-
ing to mode of delivery of the trial decision aids.
Benefits cited for the paper format included the ability
to take it away to discuss with others [11]. However,
others would have preferred it in electronic format, and
several noted the importance of context with regard to
the trial population being recruited when considering
options about delivery [11]. Mode of delivery should be
considered during development with the potential to
adapt delivery method according to local parameters or
specific patient preferences. The results of this explora-
tory pilot have been published elsewhere [11].
Stakeholder input
Involvement of multiple stakeholders and iterative
rounds of empirical, formative research are essential in
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Fig. 1 Content mapping of International Patient Decision Aid Standards (IPDAS)/literature on informed consent for trials/informed consent
guidelines. Items with convergence across different concepts. Items that could not be mapped to overlapping concepts
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developing an intervention that is both acceptable and
implemented by all end users. In the case of trial partici-
pation decision aids, we believe that it is important to
consider the perspectives of all those who have a stake
in the intervention, from designers (trial managers, clini-
cians and methodologists) to reviewers (ethics commit-
tee and sponsor) and consumers (potential trial
participants and deliverers such as research nurses) [26].
In our pilot assessment of acceptability, we included a
range of stakeholders, specifically research nurses, trial
managers, ethics committee chairs, clinical investigators,
and potential trial participants [24]. This process of
Table 2 Example information items identified from Delphi
survey and patient information leaflet review and included in
prototype decision-aid development
Section Item
A The decision support tool
development process
Finding out what information
potential participants need to
prepare them to discuss trial
participation
The decision support tool was
tested out with recruiters who
are actively engaged in discussing
trials with potential participants.
B Providing information about
trial participation and
standard care
The decision (i.e., trial participation
or not) that needs to be
considered is adequately described.
The decision support tool presents
information about the advantages/
benefits of trial participation.
The decision support tool presents
information about the advantages/
benefits of non-participation.
The decision support tool explains
that taking part in the trial is
voluntary.
C Presenting information on
the likelihood (i.e., chance) of
receiving different treatments
The decision support tool presents
textual information (i.e.,
information in words) on the
chances of receiving specific
treatments. For example, for a trial
of surgery versus medical
treatment, you have a 1 in 2
chance of getting surgery if you
take part in the trial or 100%
chance of getting medical
treatment if you do not take part
in the trial.
The decision support tool provides
more than one way of explaining
the chances (e.g., words, numbers
and diagrams).
The decision support tool presents
information about advantages and
disadvantages of trial participation
that includes the likelihood that
they will happen.
D Determining what matters to
participants
The decision support tool
describes the features of trial
participation and standard care to
help participants imagine what it is
like to experience these options.
For example, “Surgery A may result
in pain in your right knee. People
who experience this pain may find
it hard to move around following
surgery”.
The decision support tool asks
participants to think about which
advantages and disadvantages of
trial participation and standard
care matter most to them.
E Using stories from
other participants
The decision support tool provides
stories of other participants’
experiences of deciding to
participate (or not) in a trial.
Table 2 Example information items identified from Delphi
survey and patient information leaflet review and included in
prototype decision-aid development (Continued)
Section Item
The decision support tool provides
stories that represent a range of
experiences (positive and negative)
of taking part (or not) in a trial.
F Decision guidance The decision support tool provides
a step-by-step way to make a
decision about trial participation
(e.g., by using a list or worksheet
that outlines the steps or by
developing the decision support
tool in such a way that it guides
the participant through the
decision).
G Disclosing conflicts
of interest
The decision support tool reports
who is organising and funding
the research.
The decision support tool contains
details of who has reviewed (from
both a scientific and ethical
perspective) the trial.
H Balancing the
presentation of options
The advantages and disadvantages
of trial options and standard care
are presented with equivalent
detail (e.g., using similar fonts,
order, and display of statistical
information).
I Using plain language The information is written at a
level that can be understood by at
least half of the participants for
whom it is intended.
The information provides ways
other than reading (e.g., audio,
video, or in-person discussion) to
help participants understand
information.
J Basing included information
on up-to-date scientific
information
The decision support tool
describes the quality of the
scientific evidence (e.g., quality
of research studies).
The decision support tool uses
evidence taken from studies on
participants that are similar to the
participants who would use the
information (e.g., age and gender).
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engagement with intervention “users” (not just during
feasibility but throughout the process of development)
has similarities with user-centred design [30]. User-
centred design is an iterative method for optimising
“user” experience (and, indirectly, effectiveness) of a
service, system or product [30]. This framework is being
adopted by researchers as a way to review user involve-
ment (and develop best practice guidance) during the
development of treatment decision aids [31].
Assessment of acceptability
It is further recommended by the ODSF that the chosen
method of assessment (i.e., large-scale investigation or
small-scale in-depth exploration) should be appropriate
to answer the specific concerns the research team have
about acceptability [22]. Our study used semi-structured
qualitative interviews to explore stakeholders’ perspec-
tives about the acceptability and (potential) usefulness of
the prototype decision-aid interventions [24]. The
Fig. 2 Sample pages from prototype decision aids to support trial participation decisions. eTHoS Prototype Decision Aid SUSPEND Prototype Decision Aid
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benefits of this approach were that it allowed an in-
depth assessment of individuals’ perspectives on the pros
and cons of trial participation decision aids and allowed
clarification of any misunderstandings in relation to the
intervention. However, this did mean that the included
sample was small and this in itself may present limitations
(i.e., were the perspectives of those in our sample different
from others in the population). Some studies investigating
the usefulness of treatment decision aids have used quan-
titative surveys to assess intervention acceptability [32]. It
may also be that, through rounds of testing and user
feedback, small exploratory studies assessing acceptability
could feed into larger-scale survey work. This survey work
may have the potential to facilitate the implementation
phase through engaging with end users early on.
Evaluation
The final phase of any decision-aid development process
is the formal evaluation.
a. Choice of evaluation design
The most robust method to evaluate the large-scale ef-
fectiveness of any healthcare intervention is acknowledged
to be the randomised controlled trial (RCT) as it mini-
mises selection bias and allows reliable estimates of effect
to be concluded [33]. In the context of evaluating a deci-
sion aid, this would require embedding a formal RCT of
the effectiveness of decision aid versus standard trial infor-
mation on the consent process within a host clinical trial.
It is also important to consider what type of randomised
design (e.g., an individually randomised design and a
cluster trial design) is most appropriate to assess the
effectiveness of these interventions. Of the randomised
comparisons of trial participation decision aids (defined
using the IPDAS [34]) conducted to date, all have been
conducted as individually randomised two-arm parallel
trials [14–16]. However, the use of a stepped-wedge or
cluster design, where groups/clusters (e.g., sites) are
randomised to use the decision aid (or the traditional
consent process), may be more appropriate as it would
minimise any contamination effect that might be intro-
duced through the training of staff in the use of the deci-
sion aid. One such study is ongoing: a stepped-wedge
RCT to assess effectiveness of a decision aid to reduce
decisional conflict in breast cancer patients considering
participation in a prospective cohort study [17].
Given that a decision aid is a complex intervention
with interacting components (the decision-aid process
involves interactions between a participant, the aid and
the person delivering the aid), it is also important for the
evaluation to be designed to ensure that any assessment
of effectiveness can be directly attributed to the
decision-aid process itself (and not to any wider system
influences such as provision of supplementary leaflets or
information via the person delivering the aid). A concur-
rent process evaluation (see below) will aid the formal
evaluation in this regard.
b. Choice of primary outcome
Another key consideration in the design of the eva-
luation is the choice of primary outcome and any related
secondary outcomes and the relevance of these for the
decision-aid trial and the host trial (i.e., impacts on
recruitment and retention). All of the previous studies
have chosen decisional conflict or knowledge (or both) as
their primary outcome [14–17]. Whether or not these are
the most appropriate primary outcomes to use for the
evaluation of a trial participation decision aid is not yet
clear as there has been little assessment to date as to
whether the users of these aids—potential (and expe-
rienced) trial participants—consider these outcomes to be
meaningful. Further input from these stakeholders is
required to identify what outcomes they consider should
best be used to determine whether these decision support
interventions are “effective”. The formal effectiveness
evaluation of our decision aid has yet to be conducted, but
at this time our anticipated primary outcome is decisional
conflict (i.e., how certain someone is of their decision to
participate in the trial or not). However, this may be
amended in the light of work which is under way (led by
our group) to explore stakeholders’ perceptions and build
consensus on what outcomes should be considered the
core for the evaluation of interventions to improve
informed consent to trials [35]; this will inform future
evaluations in this space. Also worth considering are
longer-term outcomes of trial participation decision
aids such as trial retention and future research partici-
pation. These trial related outcomes coudl be consid-
ered as proxies for decision quality but would have
more direct relevance to trial delivery.
c. Role of process evaluations
Process evaluations may also be helpful to ensure that
trial participation decision aids are being delivered as
intended (in other words, to assess fidelity of the inter-
vention in practice). Evidence from a meta-analysis of
how clinicians use decision aids in practice highlighted
that fidelity to usage instructions of treatment decision
aids (in randomised comparisons) was suboptimal and
that, in effect, the benefit observed may be greater when
used as intended [36]. Process evaluations can also pro-
vide important insights for implementation in practice.
For example, the study by Politi et al. [15] measured
three “implementation outcomes” in their evaluation,
namely “time spent on the website, number of visits to
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the website, and number of participants who visited each
page of the website in the [decision aid] group”. Any
wider unanticipated impacts on the participant or the
wider healthcare delivery system induced by the intro-
duction of the decision aid can also be captured through
a process evaluation.
d. Reporting of the evaluation
It is important that the results of any evaluation be
reported in a detailed and informed manner. Several pub-
lished reporting guidelines are likely to be relevant and
should be considered. These include the Consolidated
Standards of Reporting Trials (CONSORT) statement for
the reporting of any randomised evaluation [37] or the
cluster [38] or stepped-wedge [39] CONSORT extensions
as appropriate. The use of the TIDIER (template for inter-
vention description and replication) guidance to ensure
adequate reporting of the decision-aid intervention will
also be key to allow appropriate replication of the decision
aid and to include key aspects of delivery with regard to
“who” delivered the decision aid [40]. As decision aids are
usually evaluated within a host trial, the reporting guidance
for embedded trials should also be considered [41].
Implementation
One of the biggest challenges for treatment and screening
decision aids to date has been mobilisation of findings
from evidence into practice and wide scale-up and
adoption of these effective interventions into routine
care [42]. A range of factors have been put forward as
barriers to their adoption in practice, and many focus
on changes required at a structural, organisational and
individual level [42]. However, the routes to implemen-
tation of trial participation decision aids (should further
studies evidence benefits) may be less problematic
given that many of the structural (legislative and regu-
latory requirements for informed consent to trials) and
organisational (research nurses and others with a dedi-
cated role to seek consent for trials and trial teams with
dedicated roles to generate participant information)
pathways are already in place. However, for full scale-
up, there are important considerations in relation to
training those tasked with delivering the trial participa-
tion decision aids and ensuring that individuals are not
left alone to decide but rather are guided and coached
through the decision-making process. Widespread
adoption will also require that policy makers recognise
the potential added value that these interventions bring
to informed choices about trial participation compared
with the status quo. As such, the development of a for-
mal plan for implementation and scale-up must also be
considered during the design and evaluation of trial
participation decision aids.
Fig. 3 Development and evaluation process for decision aids for people considering trial participation. Adapted from the Medical Research
Council (MRC) guidance on developing and evaluating complex interventions and the Model Development Process for Decision Aids (Coulter et
al. 2013 [19], Craig et al. 2008 [25]).
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However, given the context in which decision aids to
support trial participation are set (i.e., a live time-limited
RCT), both evaluation and implementation must be time-
sensitive. Treatment and screening decision aids, once
developed, can be effectively used in perpetuity but this is
not the case for a trial decision aid. Each trial decision aid
is bespoke and has only the lifetime of its host trial. As
such, implementation and probably evaluation need to be
conceived as much more rapid-cycle than normal. The
decision-aid work needs to be finished in the feasibility
phase to make it fit for purpose rather than an activity
bigger than the trial itself. Whilst there may be enthusiasm
from trial teams to develop and implement these tools for
trials (unpublished data), ensuring that the development
of trial participation decision aids is achieved in a
resource-efficient manner (in terms of time, money
and expertise) will be key to their success.
A proposed integrated framework for the development
and evaluation of trial participation decision aids
Whilst frameworks do exist to help with the development
of decision aids for use in clinical treatment decisions,
there are no parallel frameworks for the development of
decision aids for use in the context of research partici-
pation and clinical trial participation. Also, little attention
has previously been given to evaluation considerations
(and none has acknowledged the cross-learning to deci-
sion aids from the complex intervention evaluation litera-
ture). We have therefore developed a new and expanded
framework to help inform the development and evaluation
of trial participation decision aids (Fig. 3). This integrates
insights from the MRC complex intervention framework
(which we have used as the foundation of this augmented
framework), theoretical insights from the ODSF, pers-
pectives integrated from the wider decision-aid literature
(including the model development process for treatment
decision aids presented by Coulter et al. in 2013 [19]), the
complex intervention evaluation literature, and the
experiential learning from our empirical testing process.
Our proposed model is presented in Fig. 3.
Conclusions
Building on insights from the decision-aid literature, the
evaluation literature and empirical testing, we have
developed a new and augmented framework that provides
much-needed guidance on the considerations required to
develop and evaluate decision aids for clinical trial partici-
pation decisions in a robust fashion. Whilst presenting
considerations as a worked example, the proposed frame-
work can be used as a systematic and rigorous develop-
ment and evaluation process for trial participation
decision aids which aligns with current guidance on both
complex intervention and decision-aid development.
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